ClinicalTrials.gg
CompletedNCT02412111Updated Jan 8, 2019Results posted

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

A Phase 3 interventional study of Ivacaftor and Tezacaftor/Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 68 sites in 10 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2019-01-08.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.

Enrollment
21st of 84
156 · median 70
Started
2015
with 7 others
Phase 3
45 of 84
none open now
Registered
32nd of 84
by date
Lead sponsor
74 of 84
Vertex Pharmaceuticals Incorporated

Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 21st largest by enrollment, is one of 8 that started in 2015, is one of 45 in phase 3, and was the 32nd registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ivacaftor

ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies testing ivacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, double-blind, ivacaftor-controlled, parallel-group, multicenter study of tezacaftor in combination with ivacaftor in subjects aged 12 years and older with CF who are heterozygous for the F508del-CFTR mutation and a second CFTR allele with a gating defect that is clinically demonstrated to be ivacaftor responsive.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Heterozygous for F508del-CFTR mutation and a second CFTR allele with a gating defect that is clinically demonstrated to be ivacaftor responsive
  • ≥40% and ≤90% of predicted normal for age, sex, and height during screening
  • Stable CF disease as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject.
  • Pregnant and nursing females (females of must have a negative pregnancy test at Screening and Week -4 Visits).
  • Sexually active subjects of who are not willing to follow the requirements
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    Ivacaftor (Run-in Period)

    Ivacaftor 150 milligram (mg) tablet orally every 12 hours for 4 weeks.

    Drug: Ivacaftor

  • Experimental
    VX-661 + Ivacaftor (Active comparator period)

    VX-661 100 mg and ivacaftor 150 mg fixed-dose combination tablet orally once daily in the morning and ivacaftor 150 mg tablet orally once daily in the evening for 8 weeks.

    Drug: Ivacaftor · Drug: Tezacaftor/Ivacaftor

  • Active comparator
    Ivacaftor monotherapy (Active comparator period)

    Ivacaftor 150 mg tablet orally every 12 hours as monotherapy for 8 weeks.

    Drug: Ivacaftor

Interventions

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: Baseline, Through Week 8

Secondary outcomes

  1. Relative Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: Baseline, Through Week 8

  2. Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline Through Week 8

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: Baseline, Through Week 8

  3. Absolute Change From Baseline in Sweat Chloride Through Week 8

    Sweat samples were collected using an approved collection device.

    Time frame: Baseline, Through Week 8

  4. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Baseline up to Week 16

  5. Trough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolites (M1-VX-661), Ivacaftor (IVA) and IVA Metabolite (M1-IVA)

    Time frame: Predose on Week -2 for Run-in period; Pre-dose on Week 2 for Active comparator period

07

Results

Posted Jan 8, 2019

Participant flow

Ivacaftor Run-in Period (4 Weeks)
Participant flow — Ivacaftor Run-in Period (4 Weeks)
MilestoneIvacaftor (Run-in Period)VX-661 + Ivacaftor (Active Comparator Period)Ivacaftor Monotherapy (Active Comparator Period)
Started15600
Completed15300
Not completed300
Withdrew: Did not meet eligibility criteria100
Withdrew: Participants refused further dosing200
Active Comparator Period (8 Weeks)
Participant flow — Active Comparator Period (8 Weeks)
MilestoneIvacaftor (Run-in Period)VX-661 + Ivacaftor (Active Comparator Period)Ivacaftor Monotherapy (Active Comparator Period)
Started07675
Full analysis set07674
Completed07569
Not completed016
Withdrew: Adverse event002
Withdrew: Participants refused further dosing001
Withdrew: Lost to follow-up001
Withdrew: Other non-compliance010
Withdrew: Other002

Outcome measures

PrimaryAbsolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
Baseline, Through Week 8
Reported as:
Least squares mean · Percent predicted of FEV1
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8
Percent predicted of FEV1VX-661 + Ivacaftor (Active Comparator Period)Ivacaftor Monotherapy (Active Comparator Period)
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 80.5 ± 0.40.2 ± 0.4
Statistical analysis
  • VX-661 + Ivacaftor (Active Comparator Period) vs Ivacaftor Monotherapy (Active Comparator Period) · Mixed Model for Repeated Measures (MMRM) · p = = 0.5846 · Least square (ls) mean difference: 0.3 · 95% CI -0.8 to 1.4
SecondaryRelative Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
Baseline, Through Week 8
Reported as:
Least squares mean · Percent change
Relative Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8
Percent changeVX-661 + Ivacaftor (Active Comparator Period)Ivacaftor Monotherapy (Active Comparator Period)
Relative Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 81.3 ± 0.60.5 ± 0.6
Statistical analysis
  • VX-661 + Ivacaftor (Active Comparator Period) vs Ivacaftor Monotherapy (Active Comparator Period) · Mixed models Repeated Measures (MMRM) · p = = 0.3860 · Least square mean difference: 0.8 · 95% CI -1.0 to 2.6
SecondaryAbsolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline Through Week 8

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
Baseline, Through Week 8
Reported as:
Least squares mean · units on a scale
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline Through Week 8
units on a scaleVX-661 + Ivacaftor (Active Comparator Period)Ivacaftor Monotherapy (Active Comparator Period)
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline Through Week 80.7 ± 1.3-2.1 ± 1.3
Statistical analysis
  • VX-661 + Ivacaftor (Active Comparator Period) vs Ivacaftor Monotherapy (Active Comparator Period) · Mixed models Repeated Measures (MMRM) · p = = 0.1236 · Least square mean difference: 2.8 · 95% CI -0.8 to 6.4
SecondaryAbsolute Change From Baseline in Sweat Chloride Through Week 8

Sweat samples were collected using an approved collection device.

Time frame:
Baseline, Through Week 8
Reported as:
Least squares mean · Millimoles per liter
Absolute Change From Baseline in Sweat Chloride Through Week 8
Millimoles per literVX-661 + Ivacaftor (Active Comparator Period)Ivacaftor Monotherapy (Active Comparator Period)
Absolute Change From Baseline in Sweat Chloride Through Week 8-7.9 ± 1.7-2.1 ± 1.8
Statistical analysis
  • VX-661 + Ivacaftor (Active Comparator Period) vs Ivacaftor Monotherapy (Active Comparator Period) · Mixed models Repeated Measures (MMRM) · p = = 0.0216 · Least square mean difference: -5.8 · 95% CI -10.7 to -0.9
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
Baseline up to Week 16
Reported as:
Number · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsIvacaftor (Run-in Period)VX-661 + Ivacaftor (Active Comparator Period)Ivacaftor Monotherapy (Active Comparator Period)
Participants with AEs665054
Participants with SAEs247
SecondaryTrough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolites (M1-VX-661), Ivacaftor (IVA) and IVA Metabolite (M1-IVA)
Time frame:
Predose on Week -2 for Run-in period; Pre-dose on Week 2 for Active comparator period
Reported as:
Mean · nanogram per milliliter (ng/mL)
Trough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolites (M1-VX-661), Ivacaftor (IVA) and IVA Metabolite (M1-IVA)
nanogram per milliliter (ng/mL)Ivacaftor (Run-in Period)VX-661 + Ivacaftor (Active Comparator Period)Ivacaftor Monotherapy (Active Comparator Period)
IVA812 ± 6151000 ± 742740 ± 464
M1-IVA1590 ± 9561830 ± 10101450 ± 828
VX-661—2520 ± 1490—
M1-VX-661—4870 ± 1750—

Adverse events

Collected over Baseline up to Week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ivacaftor (Run-in Period)0/156 (0%)2/156 (1.3%)24/156 (15.4%)
VX-661 + Ivacaftor (Active Comparator Period)0/76 (0%)4/76 (5.3%)25/76 (32.9%)
Ivacaftor Monotherapy (Active Comparator Period)0/75 (0%)7/75 (9.3%)32/75 (42.7%)
Most frequent serious events
Most frequent serious events
EventIvacaftor (Run-in Period)VX-661 + Ivacaftor (Active Comparator Period)Ivacaftor Monotherapy (Active Comparator Period)
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations1/1562/765/75
Idiopathic intracranial hypertensionNervous system disorders0/1560/761/75
Suicidal ideationPsychiatric disorders0/1560/761/75
Face oedemaGeneral disorders0/1561/760/75
Acute kidney injuryRenal and urinary disorders0/1561/760/75
UrticariaSkin and subcutaneous tissue disorders0/1561/760/75
Infective exacerbation of bronchiectasisInfections and infestations0/1561/760/75
InfluenzaInfections and infestations0/1561/760/75
Human rhinovirus test positiveInvestigations1/1560/760/75
PancreatitisGastrointestinal disorders1/1560/760/75
Most frequent other events
Most frequent other events
EventIvacaftor (Run-in Period)VX-661 + Ivacaftor (Active Comparator Period)Ivacaftor Monotherapy (Active Comparator Period)
CoughRespiratory, thoracic and mediastinal disorders12/15612/7612/75
Sputum increasedRespiratory, thoracic and mediastinal disorders8/1564/767/75
Viral upper respiratory tract infectionInfections and infestations1/1564/766/75
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations2/1566/764/75
HeadacheNervous system disorders10/1566/764/75
FatigueGeneral disorders4/1565/762/75
HaemoptysisRespiratory, thoracic and mediastinal disorders3/1563/764/75
NauseaGastrointestinal disorders3/1560/764/75
DizzinessNervous system disorders2/1564/760/75
DiarrhoeaGastrointestinal disorders2/1564/761/75

Baseline characteristics

Baseline analysis population included all participants who were included in Full Analysis Set for active comparator period (all randomized participants who have received at least 1 dose of blinded study drug during the active comparator treatment period.)

Age, Continuous
Age, Continuous(years)VX-661 + Ivacaftor (Active Comparator Period)Ivacaftor Monotherapy (Active Comparator Period)Total
Mean33.0 ± 13.131.8 ± 11.132.4 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)VX-661 + Ivacaftor (Active Comparator Period)Ivacaftor Monotherapy (Active Comparator Period)Total
Female323466
Male444084
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VX-661 + Ivacaftor (Active Comparator Period)Ivacaftor Monotherapy (Active Comparator Period)Total
Hispanic or Latino011
Not Hispanic or Latino7672148
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VX-661 + Ivacaftor (Active Comparator Period)Ivacaftor Monotherapy (Active Comparator Period)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American202
White7372145
More than one race000
Unknown or Not Reported123
08

Study locations

68 sites
  • Birmingham, Alabama, United States
  • Oakland, California, United States
  • San Diego, California, United States
  • Aurora, Colorado, United States
  • Washington, District of Columbia, United States
  • Orlando, Florida, United States
  • Augusta, Georgia, United States
  • Indianapolis, Indiana, United States
  • Lexington, Kentucky, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Detroit, Michigan, United States
  • Grand Rapids, Michigan, United States
  • Saint Louis, Missouri, United States
  • Omaha, Nebraska, United States
  • Lebanon, New Hampshire, United States
  • Manchester, New Hampshire, United States
  • Morristown, New Jersey, United States
  • New Brunswick, New Jersey, United States
  • Albany, New York, United States
  • New York, New York, United States
  • Cincinnati, Ohio, United States
  • Toledo, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Knoxville, Tennessee, United States
  • Nashville, Tennessee, United States
  • Houston, Texas, United States
  • Salt Lake City, Utah, United States
  • Morgantown, West Virginia, United States
  • Chermside, Australia
  • Clayton, Australia
  • Melbourne, Australia
  • South Brisbane, Australia
  • Westmead, Australia
  • Innsbruck, Austria
  • Bruxelles, Belgium
  • Gent, Belgium
  • Leuven, Belgium
  • Calgary, Canada
  • Toronto, Canada
  • Vancouver, Canada
  • Paris Cedex 14, France
  • Dresden, Germany
  • Erlangen, Germany
  • Essen, Germany
  • Frankfurt, Germany
  • Giessen, Germany
  • Heidelberg, Germany
  • Jena, Germany
  • Munchen, Germany
  • Cork, Ireland
  • Dublin, Ireland
  • Bari, Italy
  • Milano, Italy
  • Roma, Italy
  • Belfast, United Kingdom
  • Birmingham, United Kingdom
  • Cardiff, United Kingdom
  • Glasgow, United Kingdom
  • Leeds, United Kingdom
  • London, United Kingdom
  • Manchester, United Kingdom
  • Newcastle, United Kingdom
  • Southampton, United Kingdom
09

References and documents

Publications

  • McKone EF, DiMango EA, Sutharsan S, Barto TL, Campbell D, Ahluwalia N, Higgins M, Owen CA, Tullis E. A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation. J Cyst Fibros. 2021 Mar;20(2):234-242. doi: 10.1016/j.jcf.2020.11.003. Epub 2020 Dec 16. PubMed 33339768 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Sep 2017, 27 months.

Results were first posted in Jan 2019, 1 year 4 months after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 27 months is close to that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2015
First posted
Apr 8, 2015
StartActual
Jun 2015
Primary completionActual
Sep 2017
CompletionActual
Sep 2017
Results first posted
Jan 8, 2019
Last update
Jan 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02412111
Responsible party
Sponsor
First posted
Apr 8, 2015
Start date
Jun 2015
Primary completion
Sep 2017
Completion
Sep 2017
Results posted
Jan 8, 2019
Last update
Jan 8, 2019

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ivacaftor · Tezacaftor

Start the discussion